Профиль

Less can be more 📊 The multicentre E-PEC trial shows a clear shift in #endometrial #cancer #surgery, with increasing use of sentinel lymph node procedures and fewer systematic lymphadenectomies, reflecting a move toward less invasive staging link.springer.com/article/10.1...

Timely diagnosis of invasive mycoses saves lives 🦠 @efisg-escmid.bsky.social study reveals disparities in access to diagnostics and therapies across #LATAM #Caribbean, highlighting urgent need to strengthen laboratory capacity and improve access to essential drugs www.nature.com/articles/s41...

🚨 Metapneumovirus (#hMPV) causes severe disease in hem_onc patients, with ICU admission and mortality rates comparable to influenza and COVID-19. Yet it remains largely overlooked. 🎥 Watch our @vumediid.bsky.social presentation based on the #EPICOVIDEHA registry: www.vumedi.com/video/human-...

Human Metapneumovirus (hMPV) Outcomes in Patients With Hematologic Malignancies: Insights From the EPICOVIDEHA/EPIRESEHA RegistryA video from Jon Salmanton-García, posted on Jun 3, 2026.www.vumedi.com

Seeing our research become one of the most read in @AjHematology is incredibly moving. This recognition belongs to the entire #EPICOVIDEHA-EPIRESEHA network! 🩺✨ Your interest gives true meaning to our scientific work. 🔗 onlinelibrary.wiley.com/doi/10.1002/... @olivercornely.bsky.social

🚢🦠 @cmijournal.bsky.social on #Andes #hantavirus outbreak linked to #MVHondius Key reminder of how zoonoses, global travel, and confined settings can rapidly evolve into multinational public health challenges. #OneHealth #EmergingInfections www.clinicalmicrobiologyandinfection.org/article/S119...

Andes hantavirus outbreak on a cruise ship - an ESCMID Emerging Infections Subcommittee (EIS) rapid assessmentThe ongoing cluster of hantavirus infections associated with the cruise ship MV Hondius represents an unusual but instructive event at the intersection of zoonotic spillover, human mobility, confined ...www.clinicalmicrobiologyandinfection.org

Fungi are levelling up and we aren't ready. 🍄⚠️ Climate change is eroding our "thermal shield," training fungi to survive human body heat. The stats: 💀 3.8M deaths/year 💊 Rising drug resistance 🌍 Rapid geographic spread Time for #OneHealth www.clinicalmicrobiologyandinfection.org/article/S119...

🦟 Dengue is not benign in immunocompromised patients #DANGO registry study from the 2023–2024 Argentina 🇦🇷 outbreak - 64% hospitalized - 90% thrombocytopenia - 6% mortality - Transfusion-associated cases Wake-up call for clinicians in endemic regions! onlinelibrary.wiley.com/doi/10.1111/...

Honoured to be re-elected to the Executive Committee of the European Fungal Infection Study Group (2026–2028) within @escmid.bsky.social Thank you for the trust😊 Full election results: www.escmid.org/fileadmin/es...

‪TDM in hematology... 🔎 209 physicians | 32 countries ✅ 97% access ✅ 71% adapt treatment ⏱ Faster turnaround = more action 🚀 Expanding to targeted therapies 💡 From classical monitoring to precision medicine. 📖 www.mjhid.org/mjhid/articl... @jannikstemler.bsky.social @olivercornely.bsky.social

youtu.be/1EsYHcRQZ8g?...

hMPV in Hematologic Malignancies: Key Insights from EPICOVIDEHA/EPIRESEHAYouTube video by IDIM IDIMyoutu.be

hMPV in haematological malignancy is serious 📊 130 pts 64% hospitalized 19% ICU 8% 30-day mortality ⚠️ Severity ≈ influenza & COVID-19 ❌ No vaccine ❌ No targeted treatment hMPV is not benign in immunocompromised patients We need awareness, prevention + therapies academic.oup.com/ofid/advance...

Presented at the @dzif.bsky.social @DGI Annual Meeting 🇩🇪 🔎 P-I-21: Clinical features and outcomes of dengue in hematological malignancies 💊 P-I-22: Use of ceftazidime–avibactam in severe bacterial superinfections 🤝 Strong Argentine–German collaboration 🇦🇷🇩🇪

Final call – 3 days left! We seek input on pediatric infectious diseases (PID) postgraduate training from Iceland🇮🇸 Liechtenstein🇱🇮 Lithuania🇱🇹 Montenegro🇲🇪 North Macedonia🇲🇰 United Kingdom🇬🇧 Even confirmation of no programme is valuable Please share: www.surveymonkey.com/r/FNW5GWV

ESPID PID European Training SurveyTake this survey powered by surveymonkey.com. Create your own surveys for free.www.surveymonkey.com

🧫🦠 How accessible are fungal diagnostics in Australia and New Zealand? This survey reveals strengths, gaps, and delays driven by centralised testing, highlighting urgent needs in β-D-glucan access and resistance surveillance 👉 www.sciencedirect.com/science/arti...

Always cool to be in #Lisbon, and always important to speak about #antimicrobial_resistances. Thanks to @InêsLeonorLeitão and @CarlosPalos

Invasive #Candidiasis in Contexts of Armed Conflict, High #Violence, and Forced #Displacement in #Latin_America and the Caribbean (2005–2025) www.mdpi.com/2309-608X/11...

When will feedback on LMIC studies be truly constructive? Care is done with what’s available, not from an EU/US ivory tower where guidelines are easy to follow Does judging help more than proposing? Sometimes reality ≠ guidelines And yes, this is for you, reviewer #2

@efisg-escmid.bsky.social webinar! 11 February - 18.00 CET Registration: us06web.zoom.us/webinar/regi...

📢 Survey on PID training 🇪🇺 Residents/junior specialists with PID focus—your input matters www.surveymonkey.com/r/FNW5GWV Missing input from 🇮🇸Iceland 🇽🇰Kosovo 🇱🇻Latvia 🇱🇮Liechtenstein 🇱🇹Lithuania 🇲🇪Montenegro 🇳🇱Netherlands 🇲🇰North_Macedonia Help disseminate 🙏🙏 @escmid.bsky.social @taescmid.bsky.social

🦠 Call for Papers: Fungal Infections @BioMedCentral Immunology invites submissions for our Collection on fungal pathogenesis & host immune responses. 📅 Deadline: 26 June 2026 🔗 link.springer.com/collections/... #Immunology #Mycology #FungalInfections #CallForPapers